AnaptysBio Files 8-K for Shareholder Votes & Exhibits

Ticker: ANAB · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1370053

Anaptysbio, Inc 8-K Filing Summary
FieldDetail
CompanyAnaptysbio, Inc (ANAB)
Form Type8-K
Filed DateJun 12, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, filing, financials

Related Tickers: ANAB

TL;DR

ANAB filed an 8-K for shareholder votes and financials - standard stuff.

AI Summary

AnaptysBio, Inc. filed an 8-K on June 12, 2024, to report on matters submitted to a vote of security holders and to file financial statements and exhibits. The filing does not contain specific details about the votes or financial statements themselves, but indicates their submission.

Why It Matters

This filing indicates AnaptysBio has held or is reporting on votes by its security holders and is submitting required financial documents, which are standard corporate governance and reporting procedures.

Risk Assessment

Risk Level: low — This is a routine corporate filing reporting on shareholder votes and financial statements, not indicating any specific new risks or material events.

Key Players & Entities

  • ANAPTYSBIO, INC (company) — Registrant
  • June 12, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 10770 Wateridge Circle, Suite 210, San Diego, CA 92121 (address) — Principal Executive Offices

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the summary information of the 8-K.

What financial statements and exhibits are being filed with this 8-K?

The filing states that Financial Statements and Exhibits are being filed, but the content of these documents is not detailed in the provided summary.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on June 12, 2024.

What is AnaptysBio, Inc.'s IRS Employer Identification Number?

AnaptysBio, Inc.'s IRS Employer Identification Number is 20-3828755.

What is the company's Standard Industrial Classification code?

The company's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 597 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-06-12 16:05:29

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke

Filing Documents

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 12, 2024, AnaptysBio, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders and the following proposals were adopted: 1. Election of three Class I directors, Daniel Faga, Dennis Fenton, Ph.D., and Oleg Nodelman, each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders or until such time as his or her respective successor has been duly elected and qualified or until such director's earlier resignation or removal: Nominees Shares For Shares Withheld / Abstaining Broker Non-Votes Daniel Faga 22,287,039 545,311 1,943,741 Dennis Fenton, Ph.D. 21,883,756 948,594 1,943,741 Oleg Nodelman 18,793,914 3,885,244 2,096,933 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 24,744,224 30,261 1,606 — 3. Non-binding, advisory approval of compensation paid to the Company's named executive officers: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 19,874,097 2,954,956 3,397 1,943,641 4. Approval of the amendment and restatement of the Company's 2017 Equity Incentive Plan: Shares For Shares Against Shares Withheld/Abstaining Broker Non-Votes 16,839,857 4,686,098 1,306,496 1,943,640

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 10.1 Amended and Restated 2017 Equity Incentive Plan. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: June 12, 2024 By: /s/ Eric Loumeau Name: Eric Loumeau Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.